Symbols / INKT $9.57 +4.93%
INKT Chart
About
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 44.92M |
| Enterprise Value | 36.37M | Income | -12.36M | Sales | — |
| Book/sh | -2.94 | Cash/sh | 3.04 | Dividend Yield | — |
| Payout | 0.00% | Employees | 23 | IPO | — |
| P/E | — | Forward P/E | -2.65 | PEG | — |
| P/S | — | P/B | -3.26 | P/C | — |
| EV/EBITDA | -2.97 | EV/Sales | — | Quick Ratio | 1.06 |
| Current Ratio | 1.08 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.01 | EPS next Y | -3.61 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -69.61% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 4.69M |
| Shs Float | 1.68M | Short Float | 2.13% | Short Ratio | 4.56 |
| Short Interest | — | 52W High | 76.00 | 52W Low | 6.34 |
| Beta | 0.35 | Avg Volume | 292.73K | Volume | 78.68K |
| Target Price | $39.00 | Recom | Strong_buy | Prev Close | $9.12 |
| Price | $9.57 | Change | 4.93% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$39.00
Mean price target
2. Current target
$9.57
Latest analyst target
3. DCF / Fair value
$-18.31
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.57
Low
$35.00
High
$43.00
Mean
$39.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-15 | up | HC Wainwright & Co. | Neutral → Buy | $35 |
| 2025-07-15 | down | HC Wainwright & Co. | Buy → Neutral | $35 |
| 2025-07-14 | down | William Blair | Outperform → Market Perform | — |
| 2025-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-02-25 | main | HC Wainwright & Co. | Buy → Buy | $35 |
| 2024-11-15 | main | Baird | Outperform → Outperform | $4 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-10-09 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-03-21 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-08-10 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-05-12 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-04-19 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2023-03-22 | main | Evercore ISI Group | — → Outperform | $3 |
| 2023-03-22 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2022-08-10 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2022-01-24 | main | B. Riley Securities | — → Buy | $10 |
| 2021-11-09 | init | William Blair | — → Outperform | — |
| 2021-11-09 | init | Evercore ISI Group | — → Outperform | $30 |
- MiNK’s pediatric cancer cell therapy pact brings funding, revenue upside - Stock Titan ue, 17 Mar 2026 11
- MiNK Therapeutics to Report Q4 and Full Year 2025 Financial Results on March 31, 2026, Following Strategic Collaborations and Clinical Updates - Quiver Quantitative ue, 17 Mar 2026 11
- Why Did INKT Stock Jump 30% Today? - Stocktwits ue, 10 Mar 2026 10
- Understanding the Setup: (INKT) and Scalable Risk - Stock Traders Daily Sat, 14 Mar 2026 10
- MiNK Therapeutics shares jump 80% after C-Further partnership announcement - MSN Sun, 15 Mar 2026 18
- Mink Therapeutics to report fourth quarter and full year 2025 financial results and highlight platform expansion across inkt cell therapy programs - marketscreener.com ue, 17 Mar 2026 11
- Why Is MiNK Therapeutics Stock Trading Lower On Wednesday? - Sahm Wed, 11 Mar 2026 07
- Why Did MiNK Therapeutics (INKT) Stock Jump 50% Premarket Today? - Tokenist ue, 10 Mar 2026 13
- Why Is MiNK Therapeutics Stock (INKT) Up Today? - TipRanks ue, 10 Mar 2026 12
- MiNK Therapeutics (NASDAQ:INKT) Director Barbara Ryan Sells 1,300 Shares - MarketBeat Wed, 11 Mar 2026 23
- MiNK Therapeutics stock soars 80% on C-Further collaboration - Investing.com ue, 10 Mar 2026 11
- New IPF lung data: key immune cells depleted in advanced disease - Stock Titan ue, 03 Feb 2026 08
- MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs - marketscreener.com ue, 17 Mar 2026 11
- MiNK Therapeutics Partners with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers with $1.1 Million Funding - Quiver Quantitative ue, 10 Mar 2026 09
- MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally - Sahm ue, 10 Mar 2026 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1500 | 22052 | — | Sale at price 10.17 - 15.57 per share. | RYAN BARBARA A. | Director | — | 2026-03-10 00:00:00 | D |
| 1 | 500 | 5426 | — | Sale at price 10.83 - 10.86 per share. | RYAN BARBARA A. | Director | — | 2026-03-02 00:00:00 | D |
| 2 | 31474 | 349991 | — | Stock Award(Grant) at price 11.12 per share. | BUELL JENNIFER | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 3 | 31474 | 349991 | — | Stock Award(Grant) at price 11.12 per share. | BUELL JENNIFER | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 4 | 1263 | 14007 | — | Stock Award(Grant) at price 11.09 per share. | WIINBERG ULF | Director | — | 2025-12-01 00:00:00 | D |
| 5 | 1612 | 17877 | — | Stock Award(Grant) at price 11.09 per share. | CORVESE BRIAN J | Director | — | 2025-12-01 00:00:00 | D |
| 6 | 1601 | 17755 | — | Stock Award(Grant) at price 11.09 per share. | RYAN BARBARA A. | Director | — | 2025-12-01 00:00:00 | D |
| 7 | 1466 | 16258 | — | Stock Award(Grant) at price 11.09 per share. | BEHNER PETER | Director | — | 2025-12-01 00:00:00 | D |
| 8 | 1218 | 13508 | — | Stock Award(Grant) at price 11.09 per share. | KADLEC ROBERT PETER | Director | — | 2025-12-01 00:00:00 | D |
| 9 | 1128 | 12510 | — | Stock Award(Grant) at price 11.09 per share. | HOLCOMB JOHN BRADLEY M.D. | Director | — | 2025-12-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -9.80M | -22.72M | -30.83M | -9.13M |
| TotalUnusualItems | -638.05K | 0.00 | -9.40M | |
| TotalUnusualItemsExcludingGoodwill | -638.05K | 0.00 | -9.40M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -10.78M | -22.46M | -27.99M | -30.21M |
| ReconciledDepreciation | 215.44K | 204.62K | 121.75K | 77.96K |
| EBITDA | -10.43M | -22.72M | -30.83M | -18.53M |
| EBIT | -10.65M | -22.92M | -30.95M | -18.61M |
| NetInterestIncome | 172.57K | 463.26K | 253.32K | -2.43M |
| InterestExpense | 2.43M | |||
| InterestIncome | 172.57K | 463.26K | 253.32K | |
| NormalizedIncome | -10.15M | -22.46M | -27.99M | -20.82M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -10.78M | -22.46M | -27.99M | -30.21M |
| TotalExpenses | 10.65M | 22.92M | 30.95M | 18.61M |
| TotalOperatingIncomeAsReported | -11.29M | -22.92M | -30.95M | -28.36M |
| DilutedAverageShares | 3.77M | 3.44M | 3.37M | 2.60M |
| BasicAverageShares | 3.77M | 3.44M | 3.37M | 2.60M |
| DilutedEPS | -2.86 | -6.54 | -8.30 | -11.60 |
| BasicEPS | -2.86 | -6.54 | -8.30 | -11.60 |
| DilutedNIAvailtoComStockholders | -10.78M | -22.46M | -27.99M | -30.21M |
| NetIncomeCommonStockholders | -10.78M | -22.46M | -27.99M | -30.21M |
| NetIncome | -10.78M | -22.46M | -27.99M | -30.21M |
| NetIncomeIncludingNoncontrollingInterests | -10.78M | -22.46M | -27.99M | -30.21M |
| NetIncomeContinuousOperations | -10.78M | -22.46M | -27.99M | -30.21M |
| PretaxIncome | -10.78M | -22.46M | -27.99M | -30.21M |
| OtherIncomeExpense | -307.13K | -10.00 | 2.70M | -9.17M |
| OtherNonOperatingIncomeExpenses | 330.92K | -10.00 | 2.70M | 221.92K |
| SpecialIncomeCharges | 0.00 | 355.51K | ||
| OtherSpecialCharges | -355.51K | |||
| GainOnSaleOfSecurity | -638.05K | -9.75M | ||
| NetNonOperatingInterestIncomeExpense | 172.57K | 463.26K | 253.32K | -2.43M |
| TotalOtherFinanceCost | -253.32K | 2.43M | ||
| InterestExpenseNonOperating | 2.43M | |||
| InterestIncomeNonOperating | 172.57K | 463.26K | 253.32K | |
| OperatingIncome | -10.65M | -22.92M | -30.95M | -18.61M |
| OperatingExpense | 10.65M | 22.92M | 30.95M | 18.61M |
| OtherOperatingExpenses | 9.75M | |||
| ResearchAndDevelopment | 6.34M | 15.49M | 23.12M | 13.97M |
| SellingGeneralAndAdministration | 4.31M | 7.43M | 7.83M | 4.64M |
| GeneralAndAdministrativeExpense | 4.31M | 7.43M | 7.83M | 4.64M |
| OtherGandA | 4.31M | 7.43M | 7.83M | 4.64M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.96M | 3.46M | 3.39M | 3.35M |
| ShareIssued | 3.96M | 3.46M | 3.39M | 3.35M |
| NetDebt | 347.57K | |||
| TotalDebt | 4.92M | |||
| TangibleBookValue | -19.59M | -18.06M | -401.30K | 23.78M |
| InvestedCapital | -14.66M | -18.06M | -401.30K | 23.78M |
| WorkingCapital | -1.97M | -7.80M | 7.72M | 23.17M |
| NetTangibleAssets | -19.59M | -18.06M | -401.30K | 23.78M |
| CommonStockEquity | -19.59M | -18.06M | -401.30K | 23.78M |
| TotalCapitalization | -14.66M | -18.06M | -401.30K | 23.78M |
| TotalEquityGrossMinorityInterest | -19.59M | -18.06M | -401.30K | 23.78M |
| StockholdersEquity | -19.59M | -18.06M | -401.30K | 23.78M |
| GainsLossesNotAffectingRetainedEarnings | -631.58K | -430.95K | -292.47K | -625.27K |
| OtherEquityAdjustments | -631.58K | -430.95K | -292.47K | -625.27K |
| RetainedEarnings | -144.18M | -133.40M | -110.94M | -82.95M |
| AdditionalPaidInCapital | 125.23M | 115.77M | 110.83M | 107.35M |
| CapitalStock | 40.00 | 35.00 | 339.00 | 335.00 |
| CommonStock | 40.00 | 35.00 | 339.00 | 335.00 |
| TotalLiabilitiesNetMinorityInterest | 25.31M | 22.61M | 21.87M | 16.47M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 18.35M | 11.21M | 9.19M | 0.00 |
| OtherNonCurrentLiabilities | 48.07K | 108.50K | ||
| DuetoRelatedPartiesNonCurrent | 13.42M | 11.16M | 9.08M | 0.00 |
| TradeandOtherPayablesNonCurrent | 0.00 | 0.00 | 0.00 | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 4.92M | |||
| LongTermDebt | 4.92M | |||
| CurrentLiabilities | 6.96M | 11.40M | 12.68M | 16.47M |
| OtherCurrentLiabilities | 2.36M | 2.45M | 2.62M | 5.76M |
| PayablesAndAccruedExpenses | 4.60M | 8.95M | 10.06M | 10.70M |
| CurrentAccruedExpenses | 1.87M | 5.04M | 4.24M | 1.76M |
| Payables | 2.73M | 3.91M | 5.82M | 8.94M |
| DuetoRelatedPartiesCurrent | 0.00 | 5.95M | ||
| TotalTaxPayable | 0.00 | |||
| AccountsPayable | 2.73M | 3.91M | 5.82M | 3.00M |
| TotalAssets | 5.72M | 4.55M | 21.47M | 40.24M |
| TotalNonCurrentAssets | 732.93K | 953.98K | 1.07M | 606.60K |
| NetPPE | 732.93K | 953.98K | 1.07M | 606.60K |
| AccumulatedDepreciation | -524.64K | -495.64K | -283.68K | -168.60K |
| GrossPPE | 1.26M | 1.45M | 1.35M | 775.20K |
| OtherProperties | 1.26M | 1.45M | 1.35M | 775.20K |
| CurrentAssets | 4.99M | 3.60M | 20.40M | 39.63M |
| OtherCurrentAssets | 164.24K | 177.96K | 470.30K | 744.32K |
| CurrentDeferredAssets | 0.00 | |||
| PrepaidAssets | 246.60K | 53.11K | 298.67K | 1.76K |
| Receivables | 23.00K | |||
| TaxesReceivable | 23.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 4.58M | 3.37M | 19.64M | 38.89M |
| CashAndCashEquivalents | 4.58M | 3.37M | 19.64M | 38.89M |
| CashFinancial | 38.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -9.56M | -15.84M | -19.12M | -13.08M |
| RepurchaseOfCapitalStock | 0.00 | -477.64K | -157.19K | 0.00 |
| IssuanceOfDebt | 5.00M | 0.00 | 0.00 | 9.46M |
| IssuanceOfCapitalStock | 5.80M | 0.00 | 0.00 | 39.80M |
| CapitalExpenditure | -73.56K | -250.05K | -248.98K | |
| InterestPaidSupplementalData | 13.13K | 27.51K | 10.82K | 0.00 |
| EndCashPosition | 4.58M | 3.37M | 19.64M | 38.89M |
| BeginningCashPosition | 3.37M | 19.64M | 38.89M | 2.69M |
| EffectOfExchangeRateChanges | -54.70K | -25.25K | 19.39K | 16.90K |
| ChangesInCash | 1.26M | -16.24M | -19.27M | 36.18M |
| FinancingCashFlow | 10.82M | -407.17K | -155.60K | 49.26M |
| CashFlowFromContinuingFinancingActivities | 10.82M | -407.17K | -155.60K | 49.26M |
| ProceedsFromStockOptionExercised | 19.99K | 70.47K | 1.59K | 150.00 |
| NetCommonStockIssuance | 5.80M | -477.64K | -157.19K | 39.80M |
| CommonStockPayments | 0.00 | -477.64K | -157.19K | 0.00 |
| CommonStockIssuance | 5.80M | 0.00 | 0.00 | 39.80M |
| NetIssuancePaymentsOfDebt | 5.00M | 0.00 | 0.00 | 9.46M |
| NetShortTermDebtIssuance | 9.46M | |||
| ShortTermDebtIssuance | 9.46M | |||
| NetLongTermDebtIssuance | 5.00M | 0.00 | 0.00 | 9.46M |
| LongTermDebtIssuance | 5.00M | 0.00 | 0.00 | 9.46M |
| InvestingCashFlow | 0.00 | -73.56K | -250.05K | -248.98K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -73.56K | -250.05K | -248.98K |
| NetPPEPurchaseAndSale | 0.00 | -73.56K | -250.05K | -248.98K |
| PurchaseOfPPE | 0.00 | -73.56K | -250.05K | -248.98K |
| OperatingCashFlow | -9.56M | -15.76M | -18.87M | -12.83M |
| CashFlowFromContinuingOperatingActivities | -9.56M | -15.76M | -18.87M | -12.83M |
| ChangeInWorkingCapital | 459.73K | 2.90M | 8.77M | 3.74M |
| ChangeInOtherWorkingCapital | 2.23M | 2.54M | 2.98M | 3.47M |
| ChangeInPayablesAndAccruedExpense | -1.58M | 107.57K | 6.09M | -224.65K |
| ChangeInAccruedExpense | -393.77K | 2.03M | 3.42M | -72.61K |
| ChangeInPayable | -1.18M | -1.92M | 2.66M | -152.04K |
| ChangeInAccountPayable | -1.18M | -1.92M | 2.66M | -152.04K |
| ChangeInPrepaidAssets | -194.17K | 245.59K | -296.94K | 488.75K |
| OtherNonCashItems | 717.49K | -2.79M | 12.18M | |
| StockBasedCompensation | 1.81M | 3.86M | 3.03M | 1.74M |
| DepreciationAmortizationDepletion | 215.44K | 204.62K | 121.75K | 77.96K |
| DepreciationAndAmortization | 215.44K | 204.62K | 121.75K | 77.96K |
| Depreciation | 215.44K | 204.62K | 121.75K | 77.96K |
| OperatingGainsLosses | -1.97M | -266.78K | -2.79M | -355.51K |
| GainLossOnSaleOfBusiness | -185.35K | 0.00 | ||
| NetIncomeFromContinuingOperations | -10.78M | -22.46M | -27.99M | -30.21M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for INKT
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|